Telaprevir ILLUMINATE Study May Light The Way To Shorter Hep C Treatment
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Strong positive data from ILLUMINATE, the second of three Phase III studies of Vertex's hepatitis C treatment telaprevir to report, add evidence to the case the company is building for a response-guided regimen that could cut treatment time in half for many patients, potentially increasing compliance rates and leading to more cures